Cialis (Tadalafil): What to Expect Week by Week in Your First Month

How Tadalafil Works and Why Timing Matters

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in penile smooth muscle. By blocking that breakdown, tadalafil prolongs smooth-muscle relaxation and arterial inflow during sexual stimulation. The drug does not cause erections on its own; sexual stimulation is still required.

Its plasma half-life of approximately 17.5 hours is longer than sildenafil (3 to 5 hours) or vardenafil (4 to 5 hours), and that pharmacokinetic difference is the reason patients can take an on-demand dose and remain responsive through the following evening. The FDA label states that tadalafil may be taken without regard to food, which reduces the planning burden many men report with sildenafil.

PDE5 Selectivity Compared to Other Isoforms

Tadalafil has roughly 10,000-fold selectivity for PDE5 over PDE3 (cardiac) and PDE4 (pulmonary), a selectivity profile that reduces cardiac and respiratory side effects at therapeutic doses. It does have approximately 700-fold selectivity for PDE5 over PDE11, which is expressed in testicular and skeletal muscle tissue. That lower selectivity gap with PDE11 is the reason back pain and myalgia appear at slightly higher rates with tadalafil than with sildenafil. PubMed confirms this pharmacology in the original tadalafil characterization literature.

On-Demand vs. Daily Dosing: Two Different Time Courses

On-demand tadalafil (10 mg or 20 mg) is taken 30 minutes to 2 hours before anticipated sexual activity. Daily tadalafil (2.5 mg or 5 mg) is taken at the same time every day regardless of sexual activity. The two regimens produce different first-month experiences. On-demand users notice an effect within the first few doses. Daily-dose users accumulate steady-state plasma concentrations over approximately 5 days and may perceive a gradual, less dramatic improvement that becomes consistent by week 2.

Week 1: First Doses and Early Responses

The first week is largely about establishing tolerability and confirming that the drug produces a meaningful erection response for you. Most men prescribed on-demand tadalafil 10 mg will attempt their first dose within days of receiving the prescription.

What the Data Show at Day 1

A single 10 mg or 20 mg dose reaches peak plasma concentration in roughly 2 hours (range: 30 minutes to 6 hours depending on individual absorption). In the key Brock et al. Trial published in the Journal of Urology (2002, N=348), tadalafil 20 mg showed statistically significant improvement in IIEF (International Index of Erectile Function) scores compared to placebo as early as the first assessment point. Brock GB et al., J Urol 2002 specifically noted that 81% of tadalafil 20 mg attempts resulted in successful vaginal penetration versus 35% with placebo.

That 81% vs. 35% penetration-success rate in week-one users sets a reasonable expectation: not everyone responds fully on the first attempt.

Common First-Week Side Effects

Headache is the most frequently reported adverse effect in week 1. The FDA label lists headache occurring in 11% to 15% of patients on 20 mg doses. Back pain and myalgia appear in 3% to 6% of patients, typically 12 to 24 hours after the dose and resolving within 48 hours.

Flushing and nasal congestion are common and generally mild. Dyspepsia (indigestion) occurs in roughly 4% of users at the 20 mg dose.

When the First Week Goes Wrong

If you take tadalafil and experience a sudden drop in blood pressure, severe dizziness, or chest pain, stop and seek emergency care. Those symptoms may indicate a dangerous interaction with an undisclosed nitrate medication. The combination of any PDE5 inhibitor with nitrates is absolutely contraindicated because the additive vasodilation can cause profound hypotension.

Men with resting systolic blood pressure below 90 mmHg or who have had a stroke or myocardial infarction within the prior 6 months should not start tadalafil without explicit physician clearance. The ACC/AHA guidance on cardiovascular safety of PDE5 inhibitors is available here.

Week 2: Calibrating the Response

By the end of week 2, most men on on-demand dosing have attempted two to four doses and have a clearer picture of their typical response. For daily-dose users, steady-state plasma levels are now established.

Dose Titration Signals

If the 10 mg starting dose produces a partial response (erection sufficient for penetration but not fully rigid, or an erection that does not persist through intercourse), most prescribers will consider titrating to 20 mg at the week-2 to week-4 checkpoint. The FDA-approved maximum on-demand dose is 20 mg per 24-hour period.

What "Partial Response" Looks Like Clinically

Partial responders in the Brock 2002 trial still reported meaningful improvements in IIEF Erectile Function domain scores even at the 10 mg dose. The trial's responder analysis showed that 67% of men on tadalafil 10 mg achieved successful intercourse on at least 50% of attempts. Moving from 10 mg to 20 mg raised that figure to approximately 75% to 80%.

A partial response in week 2 is not a sign of treatment failure. It is a normal calibration signal.

Psychological Adaptation in Week 2

Performance anxiety often diminishes during the second week as men accumulate positive sexual experiences with tadalafil on board. This psychological effect is real and measurable. The IIEF includes a domain for sexual confidence, and clinical trial data consistently show that confidence scores improve in parallel with erection-quality scores over the first month. See the IIEF validation paper on PubMed.

Week 3: BPH Symptom Arc and Sustained ED Benefit

For men prescribed daily tadalafil 5 mg for benign prostatic hyperplasia (BPH) with or without concomitant ED, week 3 is typically when lower urinary tract symptoms (LUTS) begin to improve. The mechanism for BPH benefit is distinct from the ED mechanism but both depend on PDE5 inhibition.

The BPH Timeline

PDE5 is expressed in prostatic smooth muscle, the bladder neck, and the urethra. By reducing smooth-muscle tone in those tissues, tadalafil reduces urinary flow obstruction. In Roehrborn et al. (J Urol 2008, N=325), tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 3.8 points from baseline at week 4 versus 1.7 points for placebo (P<0.001). The full IPSS benefit in that trial continued to accrue through week 12.

Week 3 is roughly where men in that trial first crossed the threshold of "moderate improvement" on the IPSS scale.

ED Benefit at Week 3 on Daily 5 mg

Men taking daily tadalafil 5 mg for ED also continue to see gains through week 3. Steady-state plasma concentrations are well-established, and the consistent low-level PDE5 inhibition produces spontaneous erection responsiveness without requiring dose timing. A common patient experience during week 3 is noticing natural morning erections returning. That return of nocturnal and morning erections is a clinically meaningful signal of restored penile vascular function.

The HealthRX Week-3 Check-In Framework

At the week-3 mark, HealthRX clinicians evaluate patients across four domains:

1. Erection quality. Is the patient achieving IIEF Erectile Function domain scores of 22 or above (consistent with mild or no erectile dysfunction)?
2. LUTS improvement (if BPH co-indication). Has IPSS dropped by 3 or more points?
3. Tolerability. Have back pain and myalgia resolved between doses, or are they persistent?
4. Cardiovascular safety signals. Any new chest pain, exertional dyspnea, or palpitations since starting therapy?

Patients meeting all four criteria are continued on their current regimen through the full month-1 checkpoint.

Week 4: The First Formal Efficacy Assessment

The four-week mark is the standard first reassessment point used across most tadalafil clinical trials and in routine prescribing. By week 4, on-demand users have typically made five to eight dosing attempts, and daily users have 28 consecutive days of systemic drug exposure.

What the Brock 2002 Trial Found at Week 4

Brock et al. Reported that at week 4, men receiving tadalafil 20 mg had an IIEF Erectile Function domain score improvement of 7.2 points from baseline, compared to 1.5 points for placebo. The same trial reported that 81% of tadalafil-treated patients had successful vaginal penetration versus 35% with placebo. Full citation: Brock GB et al., J Urol 2002.

Those figures translate to a concrete clinical expectation: roughly 4 out of 5 men on an adequate dose should achieve penetration on any given attempt by week 4.

Assessing Non-Response at Week 4

True non-response to tadalafil 20 mg at week 4 occurs in roughly 20% of men in placebo-controlled trials. Non-responders warrant an evaluation for:

• Testosterone deficiency. Low free testosterone blunts PDE5 inhibitor response. Total testosterone below 300 ng/dL should prompt replacement therapy consideration before concluding that PDE5 inhibition has failed.
• Severe vascular disease. Significant arterial insufficiency (e.g., penile-brachial index below 0.6) reduces blood inflow regardless of smooth-muscle relaxation.
• Inadequate stimulation. Some patients do not allow enough time or context for effective sexual stimulation. Tadalafil requires arousal.
• Psychogenic ED. Psychotherapy or sex therapy may be needed in addition to pharmacotherapy.

The Endocrine Society's clinical practice guideline on male sexual dysfunction recommends testosterone evaluation before labeling a patient a PDE5 inhibitor non-responder. Endocrine Society 2010 guideline.

Switching Regimens at Week 4

Men who respond well to on-demand dosing but find the need to plan around timing burdensome may transition to daily 2.5 mg or 5 mg at the month-1 visit. The prescriber should confirm that daily dosing suits the patient's sexual frequency patterns. If sexual activity occurs twice per week or more, daily dosing is generally preferred. If frequency is once per week or less, on-demand remains the more cost-efficient choice.

Side Effects: Full First-Month Profile

Tadalafil's adverse-effect profile is well-characterized across thousands of trial participants. The side effects that appear in week 1 do not worsen across the first month for most patients.

Headache

Headache affects approximately 11% to 15% of men on 20 mg and 3% to 5% on 5 mg daily. The mechanism is PDE5-mediated vasodilation of cerebral vessels. It typically presents within 2 to 4 hours of dosing and resolves within 24 hours. Taking tadalafil with adequate hydration reduces incidence in clinical experience.

Back Pain and Myalgia

Back pain and myalgia are the adverse effects most specific to tadalafil versus other PDE5 inhibitors. They occur in 3% to 6% of patients, arise 12 to 24 hours post-dose, and usually resolve within 48 hours. The proposed mechanism is PDE11 inhibition in skeletal muscle. An over-the-counter NSAID (ibuprofen 400 mg) is an appropriate management option unless the patient has renal impairment or a GI contraindication.

Flushing and Nasal Congestion

Flushing affects roughly 4% to 5% of patients. Nasal congestion affects 3% to 4%. Both are vasodilatory effects and are dose-dependent. They rarely require dose reduction.

Visual Changes

Mild blue-tinge or increased light sensitivity (related to PDE6 inhibition in the retina) occurs rarely with tadalafil at standard doses because its selectivity for PDE5 over PDE6 is approximately 700-fold. Any sudden visual loss requires immediate discontinuation and emergency evaluation for non-arteritic anterior ischemic optic neuropathy (NAION). The FDA issued a safety communication on NAION and PDE5 inhibitors.

Priapism

Priapism (erection lasting more than 4 hours) is a rare but urological emergency. Any erection persisting beyond 4 hours requires immediate emergency department evaluation. Delay can cause permanent erectile tissue damage.

Drug Interactions to Know Before Month 1

Alpha-Blockers

Tadalafil combined with alpha-blockers (tamsulosin, doxazosin, terazosin) can cause additive hypotension. The FDA label recommends that patients be stable on alpha-blocker therapy before starting tadalafil and that the initial tadalafil dose be 5 mg. FDA label reference.

CYP3A4 Inhibitors

Tadalafil is metabolized by CYP3A4. Strong inhibitors such as ketoconazole, ritonavir, and clarithromycin can increase tadalafil plasma exposure significantly. The FDA label recommends a maximum single dose of 10 mg in patients taking ritonavir, with no more than one dose per 72-hour period.

Antihypertensives

Tadalafil alone produces a modest reduction in systolic blood pressure of approximately 5 to 8 mmHg. Combined with antihypertensive agents, this may cause symptomatic hypotension, particularly in older patients. Reporting new lightheadedness on standing is the key safety signal to watch for.

Daily Tadalafil for BPH: A Separate First-Month Arc

Men taking tadalafil 5 mg daily for LUTS/BPH have a distinct treatment arc.

IPSS Trajectory

The IPSS scale runs from 0 (no symptoms) to 35 (most severe). Clinically meaningful improvement is defined as a reduction of 3 or more points. The Roehrborn 2008 trial showed the following trajectory at standard timepoints:

• Week 2: approximately 2-point IPSS reduction with tadalafil 5 mg (near but not yet at the clinically meaningful threshold).
• Week 4: approximately 3.8-point IPSS reduction (P<0.001 vs. Placebo).
• Week 12: continued improvement, reaching approximately 5.2-point reduction.

Men should be counseled not to discontinue tadalafil for BPH before the week-4 mark simply because they do not feel dramatically better in week 1 or 2.

Urinary Flow Rate

Uroflowmetry-measured maximum flow rate (Qmax) improved by approximately 2.2 mL/s from baseline in the tadalafil 5 mg group of the Roehrborn trial versus 0.9 mL/s with placebo at week 4. That improvement in Qmax is moderate but meaningful for symptomatic relief.

The American Urological Association guideline on BPH management lists tadalafil as a first-line pharmacotherapy option alongside alpha-blockers. AUA BPH guideline, available via PubMed.

What a Successful Month 1 Looks Like: Clinical Benchmarks

By day 30, men on tadalafil for ED should be able to report:

• IIEF Erectile Function domain score of 22 or above (mild or no dysfunction range) if baseline was in the moderate range (11 to 16).
• Successful intercourse on 3 out of 4 attempts or better (consistent with the 75% to 81% responder rates in the Brock 2002 trial at adequate doses).
• Tolerability established: side effects present initially but manageable or resolved.

Men on daily tadalafil for BPH should report:

• IPSS reduction of 3 or more points from baseline.
• Subjective improvement in urinary stream force or reduction in nocturia episodes.

If neither benchmark is met, the prescriber should reassess dose, evaluate for testosterone deficiency, and screen for vascular risk factors.

As the Endocrine Society's 2010 clinical practice guideline states: "Testosterone deficiency should be excluded before a patient is labeled a non-responder to PDE5 inhibitor therapy, as normalization of testosterone may restore responsiveness." Endocrine Society guideline on male hypogonadism.